Announcement PDF RNS Number : 3748W Genedrive PLC 23 April 2021 REACH genedrive plc ("genedrive" or the "Company") Excellent performance of Genedrive® HCV -ID Kit in large multi-centre study genedrive plc (AIM: GDR), the near patient molecular diagnostics company, announces the publication of a large independent multi-centre study evaluating the real-world performance of the Genedrive® HCV -ID Kit in low and middle income countries. The study yielded sensitivity specifications of 96.2 - 100%, and specificity specifications of 98.7 - 99.5%, depending on the site or viral load. The results confirm that the Genedrive® HCV -ID Kit is effective as intended in the diagnosis of HCV infection in resource limited settings. Importantly, the authors highlight a test fail rate of only 1.6%, showing that the Genedrive® system performs to this high standard even though the system operators in the study had no previous experience in molecular testing. The study, published in the journal Diagnostics (Lamoury et al, 2021, 11, 746) was conducted in Georgia and Cameroon, and enrolled 426 participants, which had very different demographic backgrounds. The participants in the Georgia trial were almost all intravenous drug users. Intravenous drug users are a key patient population for HCV infection. The Genedrive sensitivity and specificity results were obtained by comparison to testing with the Abbott RealTime HCV Assay. The publication can be accessed on line at https://www.mdpi.com/2075-4418/11/5/746 . The study was conducted by The Foundation for Innovative New Diagnostics (FIND), with grant funding provided by Unitaid. The study's findings also corroborate other key performance capabilities of the Genedrive® HCV -ID Kit, including the ability of the kit to identify all major HCV genotypes, the utility of requiring small volumes of plasma, and the lack of hazardous chemicals in the Genedrive kits construction, allowing for normal disposal processes versus competitor products that require heat incineration. David Budd, Chief Executive Officer of genedrive plc, said: "This study is the first large scale, independent multi centre evaluation from low and middle income markets using the Genedrive HCV test. While the performance results are as expected and excellent, it is equally gratifying to see these achieved with operators with no previous experience in molecular testing. Moving testing from highly complex and automated central hospital settings towards more simple decentralised settings is a balance of technological complexity, cost, performance, and usability, which is not always an easy balance to achieve. This study is an excellent demonstration of real world performance and the ability of Genedrive to contribute to fighting HCV in resource limited settings." The Genedrive® HCV -ID Kit allows for decentralised molecular testing of Hepatitis C (HCV) by PCR, providing results within 90 minutes direct from a small plasma sample (30 µl). This allows for testing to be done outside of a large hospital facility and indeed while a patient may be waiting for a result. The assay is performed on the Genedrive® platform, the only truly portable molecular diagnostics system designed for diagnosing HCV at the point of need. For further details please contact: genedrive plc David Budd: CEO / Matthew Fowler: CFO +44 (0)161 989 0245 Peel Hunt LLP (Nominated Adviser and Joint Broker) James Steel / Victoria Erskine +44 (0)20 7418 8900 finnCap (Joint Broker) Geoff Nash / Kate Bannatyne / Alice Lane +44 (0)20 7220 0500 Walbrook PR Ltd (Media & Investor Relations) Paul McManus / Anna Dunphy +44 (0)20 7933 8780 or genedrive@walbrookpr.com +44 (0)7980 541 893 / +44 (0)7876 741 001 About genedrive plc (http://www.genedriveplc.com) genedrive plc is a molecular diagnostics company developing and commercialising a low cost, rapid, versatile, simple to use and robust point of need molecular diagnostics platform for the diagnosis of infectious diseases and for use in patient stratification (genotyping), pathogen detection and other indications. The Company has assays on market for the detection of HCV, certain military biological targets, and has tests in development for tuberculosis (mTB). The Company recently released a high throughput SARS-CoV-2 assay and has in development a Genedrive® Point of Care version of the assay, both based on Genedrive® chemistry. This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com. Reach is a non-regulatory news service. By using this service an issuer is confirming that the information contained within this announcement is of a non-regulatory nature. Reach announcements are identified with an orange label and the word “Reach” in the source column of the News Explorer pages of London Stock Exchange’s website so that they are distinguished from the RNS UK regulatory service. Other vendors subscribing for Reach press releases may use a different method to distinguish Reach announcements from UK regulatory news. RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy. END NRASEAFUEEFSEEL